AFMD
Affimed N.V.
NASDAQ · Healthcare · Biotechnology · DE
$0.18
+0.00%Year over year
Reported trailing growth
- Revenue
- -95.4%
- EBITDA
- +43.0%
- EBIT
- +39.4%
- EPS
- +44.3%
- Free cash flow
- +35.1%
- Operating cash flow
- +33.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -33.7%
- EBITDA
- -25.7%
- EBIT
- -21.0%
- Net income
- -23.2%
- EPS
- -17.4%
- Free cash flow
- -8.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2024